Clinical Trial: Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755436) titled 'Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.' on Aug. 05.

Brief Summary: This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

Study Start Date: July 23

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer Endometrial Cancer Platinum-resistant Ovarian Cancer (PROC) Metastatic Ovarian Cancer Metastatic Endometrial Cancer

Intervention: DRUG: ARR-002

ARR-002 will be administrated ...